Daily Signal · October 4, 2026

The Drug-Price Test Starts With an Address

A clinician considers a map boundary, paired folders, medicine packaging, and unequal coin stacks arranged on a desk.

On October 2, the Centers for Medicare & Medicaid Services published a final rule establishing the Global Benchmark for Efficient Drug Pricing Model. The rule takes effect November 30. Starting next year, the GLOBE Model will test a different way to calculate inflation rebates and coinsurance for a subset of expensive Medicare Part B drugs.

Where a beneficiary lives will help decide whether a claim enters the test.

What changed

CMS will randomly select ZIP Code Tabulation Areas, geographic units built by the Census Bureau from groups of ZIP codes. The agency will use each beneficiary's address of record to identify a model cohort drawn from roughly 25% of eligible Original Medicare Part B beneficiaries. Medicare Advantage members and people with certain other primary coverage are outside that cohort.

The address is only one condition. The model covers a subset of separately payable Part B drugs and biological products in specified categories. A drug must also cross a Medicare spending threshold, and the rule excludes several groups, including drugs with a Medicare-negotiated maximum fair price in effect and some products for rare diseases, cell and gene therapies, and plasma-derived products.

For eligible claims, CMS will test two methods for setting an international-price benchmark. One uses commercially available pricing data. The other uses international net-price data that manufacturers may submit voluntarily. Manufacturers of drugs included in the model must participate in the rebate process, although submitting data for the second benchmark method is voluntary.

Data collection begins January 1, 2027. Five performance years run from April 1, 2027 through March 31, 2032. Rebate invoicing and reconciliation continue through March 31, 2034.

Why it matters

A Medicare claim can now carry a hidden geographic coordinate. To verify the coinsurance calculation, a patient, provider, or auditor may need to know four things at once: whether the beneficiary was in the selected area, whether the drug was on the model list, whether the service date fell inside the test, and which benchmark applied.

That creates the possibility that two otherwise similar Original Medicare beneficiaries receiving the same included drug could face different coinsurance treatment because their addresses fall on opposite sides of the model boundary. CMS designed the geographic selection to support a comparison between the model cohort and a comparison group.

Living in a selected area does not guarantee a lower bill. The beneficiary, drug, claim, and date must all qualify. Even then, reduced coinsurance depends on the model benchmark calculation. Providers will continue to buy and bill for the drugs through Medicare Part B, while Medicare may raise its share of the allowed amount when the beneficiary's coinsurance is reduced.

The rule supplies projections and a test design, not results. It does not turn international prices directly into U.S. prices, and the model has not yet produced evidence about savings, access, or quality of care.

Watch next

The first practical records will be the selected geographic areas, the included-drug list, and CMS instructions for billing systems. Beneficiary and provider notices will show whether people can tell that a claim is inside the model before a bill arrives.

After the first performance year begins, watch the monitoring reports for changes in coinsurance, use of included drugs, access to treatment, and shifts to products outside the model. Those records will show whether a geographic payment experiment can lower patient costs without moving the expense or the behavior somewhere else.

Sources